Miragen, Servier Ink $352M Preclinical Micro-RNA Deal

Miragen Therapeutics Inc.'s preclinical micro-RNA program for cardiovascular disease captured the attention of French pharma Les Laboratoires Servier, which agreed to license rights to two lead compounds and jointly develop a third in a deal that's valued at up to $352 million but could end up being worth much more to the small biotech.